Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.